Patents by Inventor David J. Guerin

David J. Guerin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11524966
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: December 13, 2022
    Assignee: Valo Health, Inc.
    Inventors: David J. Guerin, Pui Yee Ng, Zhongguo Wang, Tatiana Shelekhin, Justin Caravella, Hongbin Li, Stephanos Ioannidis, Mary-Margaret Zablocki
  • CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS
    Publication number: 20210323975
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 21, 2021
    Inventors: David J. GUERIN, Pui Yee NG, Zhongguo WANG, Tatiana SHELEKHIN, Justin CARAVELLA, Mary-Margaret ZABLOCKI, Jennifer R. DOWNING, Hongbin LI, Stephanos IOANNIDIS
  • INHIBITING DEUBIQUITINASE USP25 AND USP28
    Publication number: 20210179628
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).
    Type: Application
    Filed: August 8, 2019
    Publication date: June 17, 2021
    Inventors: David J. GUERIN, Justin A. CARAVELLA, Hongbin LI, Steven MISCHKE, David J. RICHARD, Shawn E.R. SCHILLER, Tatiana SHELEKHIN
  • Pyrazolyl derivatives as Syk inhibitors
    Patent number: 9242984
    Abstract: The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 26, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Michelle R. Machacek, Michael D. Altman, Eric T. Romeo, Dilrukshi Vitharana, Brandon Cash, Tony Siu, Hua Zhou, Matthew Christopher, Solomon D. Kattar, Andrew M. Haidle, Kaleen Konrad Childers, Matthew L. Maddess, Michael H. Reutershan, Yves Ducharme, David J. Guerin, Kerrie Spencer, Christian Beaulieu, Vouy Linh Truong, Daniel Guay, Alan B. Northrup, Brandon M. Taoka, Jongwon Lim, Christian Fischer, John W. Butcher, Ryan D. Otte, Binyuan Sun, John Michael Ellis
  • PYRAZOLYL DERIVATIVES AS SYK INHIBITORS
    Publication number: 20150191461
    Abstract: The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Application
    Filed: June 18, 2013
    Publication date: July 9, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, Michael D. Altman, Eric T. Romeo, Dilrukshi Vitharana, Brandon Cash, Tony Siu, Matthew Christopher, Solomon D. Kattar, Andrew M. Haidle, Kaleen Konrad Childers, Matthew L. Maddess, Michael H. Reutershan, Yves Ducharme, David J. Guerin, Kerrie Spencer, Christian Beaulieu, Vouy Linh Truong, Daniel Guay, Alan B. Northrup, Brandon M. Taoka, Jongwon Lim, Christian Fischer, John W. Butcher, Ryan D. Otte, Binyuan Sun, John Michael Ellis
  • Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
    Patent number: 8329722
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: December 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • Processes and intermediates
    Patent number: 8293929
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: October 23, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
    Patent number: 8183245
    Abstract: The present invention relates to pyrazine substituted pyrrolopyridines having formula (I) useful as inhibitors of JAK kinases (JAK1, JAK2, JAK3 and/or TYK2) and/or PDK1 and for the treatment of myeloproliferative disorders or other cancers.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: May 22, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David J. Guerin, Joos Jung, Elizabeth Stanton
  • Processes and Intermediates
    Publication number: 20110071298
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Application
    Filed: October 12, 2010
    Publication date: March 24, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and intermediates
    Patent number: 7834200
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: November 16, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • THERAPEUTIC COMPOUNDS
    Publication number: 20100210623
    Abstract: The present invention relates to pyrazine substituted pyrrolopyridines which are inhibitors of JAK kinases (JAK1, JAK2, JAK3 and/or TYK2) and/or PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer.
    Type: Application
    Filed: October 21, 2008
    Publication date: August 19, 2010
    Inventors: David J. Guerin, Joon Jung, Elizabeth Stanton
  • INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1
    Publication number: 20100160309
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 24, 2010
    Inventors: Tony Siu, Jonathan Young, Micheal Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
    Publication number: 20090197908
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 22, 2006
    Publication date: August 6, 2009
    Inventors: Christopher J. Dinsmore, Ana Esther Gabarda Ortega, David J. Guerin, James P. Jewell, Jason D. Katz, Jongwon Lim, Michelle R. Machacek, Ryan D. Otte, Jonathan R. Young
  • Tyrosine kinase inhibitors
    Patent number: 7550478
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: June 23, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Christopher J. Dinsmore, Ana Esther Gabarda Ortega, David J. Guerin, James P. Jewell, Jason D. Katz, Jongwon Lim, Michelle R. Machacek, Ryan D. Otte, Jonathan R. Young
  • Tyrosine Kinase Inhibitors
    Publication number: 20090149467
    Abstract: The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: September 11, 2006
    Publication date: June 11, 2009
    Applicant: MERCK & CO., INC.
    Inventors: Christopher J. Dinsmore, David J. Guerin, Barbara Hanney, Yuntae Kim, Keith L. Spencer, Maricel Torrent
  • Processes and intermediates
    Publication number: 20090048429
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Application
    Filed: March 7, 2008
    Publication date: February 19, 2009
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and intermediates
    Patent number: 7381827
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: June 3, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian